Axicabtagene Ciloleucel,Cyclophosphamide,Fludarabine
Gilead
['pivotal trial', 'axi-cel']
- 170/180 patients randomized to axi-cel received axi-cel
- only 64/179 (36%) of soc arm actually received asct
- it does amaze me that 6 deaths in such a pivotal trial can be due to "unknown" causes (though they were almost all in the soc arm)
#asco23 
haematology registrar | @harvardmed fellow @PORTAL_research | evidence-based medicine & policy | lymphoma | myeloma | Fulbright | writer | SoMe Ed @BrJHaem